HIV / AIDS

Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.

Research suggests studies should adjust their cohort comparison group to account for demographics most represented by people living with HIV.

The Fenway Institute is hosting its upcoming Advancing Excellence in Transgender Health conference. The program will include education on transgender medical care as well as how clinicians and people within this community can interact and the former can understand the latter’s needs when it comes to preventative and acute care.

England has been meeting and exceeding its HIV diagnosis and treatment goals set by UNAIDS.

Parentless youth living on the streets had the highest rates of HIV and death, but extended-family living situations were not necessarily better than institutional care.

The importance of establishing strong relationships with patients with HIV and expert advice on building rapport.

Lifestyle management interventions that can help patients with HIV on antiretroviral therapy manage their weight.

The therapy, known as EBT-101, works by eliminating HIV-infected DNA from the genome.

To address PrEP implementation in Kenya, a team of researchers evaluated practices and contextual modifications across public HIV clinics.

Antiretroviral therapy for HIV offers a protective outcome against preterm birth for pregnant women with HIV.

The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.

Considerations for switching therapies used to manage patients with HIV following resistance or progression on prior treatment.

Drs Osama Hamdy and Tavell Kindall react to the association between weight gain and antiretroviral therapies used to treat HIV.

Higher HIV viral loads and additional heart disease factors increase the risk as well.

A small subset of people living with HIV (PLWH) can naturally suppress the virus without medication.

Changes in perceptions about the severity of HIV with advances in treatment and efforts to normalize living with the disease may create challenges for HIV prevention, a new study from the Netherlands suggests.

A discussion regarding the safety profile and use of bictegravir/emtricitabine/tenofovir alafenamide as treatment for HIV.

Interpretations of data supporting the use of single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide as treatment for patients with HIV and its effects on patient weight.

Islatravir exerts multiple mechanisms against HIV, demonstrates treatment effectiveness with doravirine, and is a potential weekly or monthly oral PrEP.

HIV coinfection was associated with a 3.7-fold increase in the risk of non-liver-related cancer among patients with hepatitis C virus infection, a new study found.

Optimizing delivery of HIV preexposure prophylaxis will take more than access to health care, according to a recent analysis of PrEP use behaviors among adults in an integrated health system.

Despite heightened cardiovascular disease (CVD) risk, too few get drugs at appropriate dose, researchers say.

Considerations for more widespread use of 2-drug regimens to treat patients with HIV.

Dr Tavell Kindall reacts to the importance of rapid initiation of antiretroviral therapy for patients with HIV.

It is important to go out into the local communities to educate people about PrEP as countries try to scale up with the World Health Organization’s (WHO) PrEP recommendations.

Global use of HIV pre-exposure prophylaxis has risen as more countries have adopted World Health Organization recommendations.

New Imbokodo findings show a 4-dose regimen was only about 25% effective in preventing HIV in at-risk women, hindering progress for the vaccine.

The adoption of numerous HIV prevention measures was associated with an 80% drop in the number of HIV diagnoses, a study evaluating the success of 56 Dean Street in London found.

Persons living with HIV are susceptible to TB and also appear at increased risk for infecting strains acquiring rifampicin-resistance.

The significance of treating HIV with single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide based on data demonstrated by the EMERALD and AMBER clinical trials.